Second and later line treatments: Anti-angiogeneic? MET inhibitors? Immunotherapy? Or just best supportive care?

Date 10 September 2017
Event ESMO 2017 Congress
Session ESMO COLLOQUIUM - Systemic treatment of unresectable hepatocellular carcinoma
Topics Anti-Cancer Agents & Biologic Therapy
Hepatobiliary Cancers
Presenter Jörg Trojan
Authors J. Trojan
  • Department Of Gastroenterology And Hepatology, University Hospital Frankfurt, 00 - Frankfurt/DE